Abemaciclib is an active pharmaceutical ingredient classified as a cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It is primarily used in the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. By inhibiting CDK4/6, abemaciclib disrupts the cell cycle, leading to reduced cancer cell spread. What is a Hormone receptor (HR)-positive? This means […]